Skip to main content
Erschienen in: Supportive Care in Cancer 3/2018

01.03.2018 | Original Article

Utility of the revised Edmonton Symptom Assessment System (ESAS-r) and the Patient-Reported Functional Status (PRFS) in lung cancer patients

verfasst von: M. N. Yogananda, Valliappan Muthu, Kuruswamy Thurai Prasad, Adarsh Kohli, Digambar Behera, Navneet Singh

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Symptom palliation is an important objective of treatment in advanced/metastatic lung cancer (LC). Significant psychological, minor physical symptoms and several social/emotional issues often go unnoticed. This prospective study aimed to evaluate utility of patients’ perspectives [self-reported symptom assessment by revised Edmonton Symptom Assessment System (ESAS-r) and self-reported functional status by Patient-Reported Functional Status (PRFS)] amongst LC patients undergoing chemotherapy.

Methods

Consecutive newly diagnosed treatment-naïve LC patients attending a tertiary referral center in North India from January 2014 to March 2015 were included. All patients received standard histology-guided platinum-doublet chemotherapy. ESAS-r and PRFS questionnaires were administered under guidance, once at the time of initial assessment/diagnosis, repeated at start of chemotherapy, before C4, and after completion of chemotherapy (end of chemotherapy (EOCTx)). Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire was also administered. Baseline and post-treatment scores were compared.

Results

Majority of 133 patients enrolled were males (86.5%,n = 115), were current/ex-smokers (81.2%, n = 108), had advanced stage [IIIB = 30.1% (n = 40), IV = 52.6% (n = 70)], and were of non-small-cell type (NSCLC;84.2%,n = 112). On baseline ESAS-r, the highest mean symptom scores were observed for tiredness followed by anorexia. Mean ESAS-r scores before C4 as well as at EOCTX were significantly better than baseline ESAS-r scores in all its components except nausea. Similarly, PRFS before C4 and EOCTx was significantly improved compared to baseline. However, Karnofsky Performance Scale (KPS) and Eastern Cooperative Oncology Group Performance Status assessed at baseline did not show significant improvement at treatment completion. FACT-L score at EOCTx showed significant improvement from baseline in physical and functional well-being domains but not for social/family and emotional well-being domains.

Conclusion

This study validated utility of ESAS-r and PRFS in Indian LC patients. These instruments should be used in routine clinical practice besides physicians’ assessment of PS (KPS/ECOG).
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Singh N, Aggarwal AN, Gupta D et al (2010) Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol 34:101–104CrossRefPubMed Singh N, Aggarwal AN, Gupta D et al (2010) Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol 34:101–104CrossRefPubMed
2.
Zurück zum Zitat Singh N, Aggarwal AN, Gupta D et al (2012) Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis 4:474–484PubMedPubMedCentral Singh N, Aggarwal AN, Gupta D et al (2012) Quantified smoking status and non-small cell lung cancer stage at presentation: analysis of a North Indian cohort and a systematic review of literature. J Thorac Dis 4:474–484PubMedPubMedCentral
4.
Zurück zum Zitat Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed
5.
Zurück zum Zitat Singh N, Behera D (2014) Palliation in metastatic non-small cell lung cancer: early integration with standard oncological care is the key. Lung India 31:317–319CrossRefPubMedPubMedCentral Singh N, Behera D (2014) Palliation in metastatic non-small cell lung cancer: early integration with standard oncological care is the key. Lung India 31:317–319CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Singh N, Aggarwal AN, Behera D (2012) Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Rev Anticancer Ther 12:1479–1495CrossRefPubMed Singh N, Aggarwal AN, Behera D (2012) Management of advanced lung cancer in resource-constrained settings: a perspective from India. Expert Rev Anticancer Ther 12:1479–1495CrossRefPubMed
9.
Zurück zum Zitat Watanabe SM, Nekolaichuk C, Beaumont C et al (2011) A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manag 41:456–468CrossRef Watanabe SM, Nekolaichuk C, Beaumont C et al (2011) A multicenter study comparing two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J Pain Symptom Manag 41:456–468CrossRef
10.
Zurück zum Zitat Dudgeon DJ, Harlos M, Clinch JJ (1999) The Edmonton Symptom Assessment Scale (ESAS) as an audit tool. J Palliat Care 15:14–19PubMed Dudgeon DJ, Harlos M, Clinch JJ (1999) The Edmonton Symptom Assessment Scale (ESAS) as an audit tool. J Palliat Care 15:14–19PubMed
11.
Zurück zum Zitat Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ et al (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
12.
Zurück zum Zitat Singh N, Aggarwal AN, Behera D et al (2010) Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival. J Thorac Oncol 5:236–239CrossRefPubMed Singh N, Aggarwal AN, Behera D et al (2010) Intercycle delays during chemotherapy of non-small cell lung cancer in a health care resource-constrained setting and their effect on overall survival. J Thorac Oncol 5:236–239CrossRefPubMed
13.
Zurück zum Zitat Singh N, Mootha VK, Madan K et al (2013) Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival. Med Oncol 30:602CrossRefPubMed Singh N, Mootha VK, Madan K et al (2013) Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival. Med Oncol 30:602CrossRefPubMed
14.
Zurück zum Zitat Singh N, Singh PS, Aggarwal AN et al (2016) Comorbidity assessment using Charlson Comorbidity Index and Simplified Comorbidity Score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer 17:205–213.e201CrossRefPubMed Singh N, Singh PS, Aggarwal AN et al (2016) Comorbidity assessment using Charlson Comorbidity Index and Simplified Comorbidity Score and its association with clinical outcomes during first-line chemotherapy for lung cancer. Clin Lung Cancer 17:205–213.e201CrossRefPubMed
15.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216CrossRefPubMed
16.
Zurück zum Zitat Common terminology criteria for adverse events, Version 3.0: cancer therapy evaluation program, 2006 Common terminology criteria for adverse events, Version 3.0: cancer therapy evaluation program, 2006
17.
Zurück zum Zitat Singh N, Aggarwal AN, Kaur J et al (2017) Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of nonsquamous NSCLC patients with pemetrexed-based chemotherapy. Am J Clin Oncol 40:75–82CrossRefPubMed Singh N, Aggarwal AN, Kaur J et al (2017) Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of nonsquamous NSCLC patients with pemetrexed-based chemotherapy. Am J Clin Oncol 40:75–82CrossRefPubMed
18.
Zurück zum Zitat Silvoniemi M, Vasankari T, Loyttyniemi E et al (2016) Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy. Anticancer Res 36:4123–4128PubMed Silvoniemi M, Vasankari T, Loyttyniemi E et al (2016) Symptom assessment for patients with non-small cell lung cancer scheduled for chemotherapy. Anticancer Res 36:4123–4128PubMed
19.
Zurück zum Zitat Seow H, Barbera L, Sutradhar R et al (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158CrossRefPubMed Seow H, Barbera L, Sutradhar R et al (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29:1151–1158CrossRefPubMed
20.
Zurück zum Zitat Montoya M, Fossella F, Palmer JL et al (2006) Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med 9:309–316CrossRefPubMed Montoya M, Fossella F, Palmer JL et al (2006) Objective evaluation of physical function in patients with advanced lung cancer: a preliminary report. J Palliat Med 9:309–316CrossRefPubMed
21.
Zurück zum Zitat Steinberg T, Roseman M, Kasymjanova G et al (2009) Prevalence of emotional distress in newly diagnosed lung cancer patients. Support Care Cancer 17:1493–1497CrossRefPubMed Steinberg T, Roseman M, Kasymjanova G et al (2009) Prevalence of emotional distress in newly diagnosed lung cancer patients. Support Care Cancer 17:1493–1497CrossRefPubMed
22.
Zurück zum Zitat Kasymjanova G, Grossman M, Tran T et al (2013) The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study. Curr Oncol 20:152–157CrossRefPubMedPubMedCentral Kasymjanova G, Grossman M, Tran T et al (2013) The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study. Curr Oncol 20:152–157CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Nowicki A, Farbicka P, Krajnik M (2015) Dejection and self-assessment of quality of life in patients with lung cancer subjected to palliative care. Contemp Oncol (Pozn) 19:491–495 Nowicki A, Farbicka P, Krajnik M (2015) Dejection and self-assessment of quality of life in patients with lung cancer subjected to palliative care. Contemp Oncol (Pozn) 19:491–495
24.
Zurück zum Zitat Taylor AE, Olver IN, Sivanthan T et al (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335CrossRefPubMed Taylor AE, Olver IN, Sivanthan T et al (1999) Observer error in grading performance status in cancer patients. Support Care Cancer 7:332–335CrossRefPubMed
25.
Zurück zum Zitat O'Brien ME, Socinski MA, Popovich AY et al (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:728–734CrossRefPubMed O'Brien ME, Socinski MA, Popovich AY et al (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:728–734CrossRefPubMed
26.
Zurück zum Zitat Langer CJ, O'Byrne KJ, Socinski MA et al (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:623–630CrossRefPubMed Langer CJ, O'Byrne KJ, Socinski MA et al (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3:623–630CrossRefPubMed
27.
Zurück zum Zitat Yenge LB, Behera D, Garg M et al (2017) Comparison of symptom score and bronchoscopy-based assessment with conventional computed tomography-based assessment of response to chemotherapy in lung cancer. J Glob Oncol 3:370–379CrossRefPubMed Yenge LB, Behera D, Garg M et al (2017) Comparison of symptom score and bronchoscopy-based assessment with conventional computed tomography-based assessment of response to chemotherapy in lung cancer. J Glob Oncol 3:370–379CrossRefPubMed
28.
Zurück zum Zitat Heedman PA, Strang P (2001) Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077–4082PubMed Heedman PA, Strang P (2001) Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 21:4077–4082PubMed
29.
Zurück zum Zitat Singh PS, Aggarwal AN, Behera D et al (2017) Simplified graded baseline symptom assessment in patients with lung cancer undergoing first-line chemotherapy: correlations and prognostic role in a resource-constrained setting. J Glob Oncol 3:54–63CrossRefPubMed Singh PS, Aggarwal AN, Behera D et al (2017) Simplified graded baseline symptom assessment in patients with lung cancer undergoing first-line chemotherapy: correlations and prognostic role in a resource-constrained setting. J Glob Oncol 3:54–63CrossRefPubMed
30.
Zurück zum Zitat Reddy SK, Parsons HA, Elsayem A et al (2009) Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 12:29–36CrossRefPubMed Reddy SK, Parsons HA, Elsayem A et al (2009) Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 12:29–36CrossRefPubMed
31.
Zurück zum Zitat Gupta M, Sahi MS, Bhargava AK et al (2016) A prospective evaluation of symptom prevalence and overall symptom burden among cohort of critically ill cancer patients. Indian J Palliat Care 22:118–124CrossRefPubMedPubMedCentral Gupta M, Sahi MS, Bhargava AK et al (2016) A prospective evaluation of symptom prevalence and overall symptom burden among cohort of critically ill cancer patients. Indian J Palliat Care 22:118–124CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Fan G, Hadi S, Chow E (2007) Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. Support Cancer Ther 4:157–162CrossRefPubMed Fan G, Hadi S, Chow E (2007) Symptom clusters in patients with advanced-stage cancer referred for palliative radiation therapy in an outpatient setting. Support Cancer Ther 4:157–162CrossRefPubMed
33.
Zurück zum Zitat Cheung WY, Le LW, Zimmermann C (2009) Symptom clusters in patients with advanced cancers. Support Care Cancer 17:1223–1230CrossRefPubMed Cheung WY, Le LW, Zimmermann C (2009) Symptom clusters in patients with advanced cancers. Support Care Cancer 17:1223–1230CrossRefPubMed
34.
Zurück zum Zitat Barbera L, Seow H, Howell D et al (2010) Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116:5767–5776CrossRefPubMed Barbera L, Seow H, Howell D et al (2010) Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116:5767–5776CrossRefPubMed
35.
Zurück zum Zitat Zeng L, Koo K, Zhang L et al (2012) Fatigue in advanced cancer patients attending an outpatient palliative radiotherapy clinic as screened by the Edmonton Symptom Assessment System. Support Care Cancer 20:1037–1042CrossRefPubMed Zeng L, Koo K, Zhang L et al (2012) Fatigue in advanced cancer patients attending an outpatient palliative radiotherapy clinic as screened by the Edmonton Symptom Assessment System. Support Care Cancer 20:1037–1042CrossRefPubMed
36.
Zurück zum Zitat Gralla RJ, Edelman MJ, Detterbeck FC et al (2009) Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 17:307–313CrossRefPubMed Gralla RJ, Edelman MJ, Detterbeck FC et al (2009) Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 17:307–313CrossRefPubMed
37.
Zurück zum Zitat Hollen PJ, Gralla RJ, Kris MG et al (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(Suppl 1):S51–S58CrossRefPubMed Hollen PJ, Gralla RJ, Kris MG et al (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(Suppl 1):S51–S58CrossRefPubMed
Metadaten
Titel
Utility of the revised Edmonton Symptom Assessment System (ESAS-r) and the Patient-Reported Functional Status (PRFS) in lung cancer patients
verfasst von
M. N. Yogananda
Valliappan Muthu
Kuruswamy Thurai Prasad
Adarsh Kohli
Digambar Behera
Navneet Singh
Publikationsdatum
01.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3887-1

Weitere Artikel der Ausgabe 3/2018

Supportive Care in Cancer 3/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.